Efficacy of Ultrasound Guided PIFB Versus Lidocaine Infusion on Postoperative Pain After Sternotomy
CompletedNot applicableNCT05885230
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Chronic pain is a common complication after cardiothoracic surgery. The prevalence of post-sternoyomy pain syndrome (PSPS) ranges from 33% to 91%. Exact pathogenetic mechanisms for developing chronic pain after sternotomy are unknown. Apart from intraoperative nerve damage and subsequent postoperative neuropathic pain, operation techniques, age, sex, pre-existing pain, genetic and psychosocial factors, severe postoperative pain, and analgesic management are suspected to have an impact on the development of PSPS .
Study details
- Official title
- The Efficacy of Ultrasound-guided Pecto-Intercostal Fascial Plain Block Versus Lidocaine Infusion on Acute and Chronic Post-sternotomy Pain; A Prospective Randomized Controlled Trial
- Conditions
- Cardiac Surgery
- Interventions
- Procedure: pecto intercostal fascial block using bupivacaine 0.25%
- Drug: lidocaine infusion
- Sponsor
- Beni-Suef University
- Start date
- 2023-06-03
- Primary completion
- 2023-12-01
- Sex
- All
- Age range
- from 18 Years to 75 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- Egypt
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. age between 18 and 75 years. 2. patient scheduled to undergo elective on-pump cardiac surgery with sternotomy. 3. American Society of Anesthesiologists classification of physical status \< IV. Exclusion Criteria: 1. emergency surgery. 2. off-pump surgery. 3. redo surgery. 4. ejection fraction less than 35%. 5. refusal of the patient. 6. known hypersensitivity to LA. 7. chronic opioid use or chronic pain patient. 8. psychiatric problems or communication difficulties. 9. liver insufficiency (defined as a serum bilirubin ≥ 34 μmol/l, albumin ≤ 35 g/dl, INR ≥ 1.7). 10. renal insufficiency (defined as a glomerular filtration rate \< 44 ml/min). 11. obstructive sleep apnea syndrom. 12. coexisting hematologic disorders. 13. pregnancy or breastfeeding.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05885230